Acquiring Company
Pyxis Oncology, Inc.
Acquired Company
Apexigen
BostonSan CarlosBiotechnologyHealthcareBiotechnologyHealth CareTherapeuticsDescription
Pyxis Oncology, Inc. (“Pyxis Oncology”) (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, and Apexigen, Inc. (Nasdaq: APGN), a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology, today announced a definitive agreement by which Pyxis Oncology will acquire Apexigen in an all-stock transaction for an implied value of $0.64 per Apexigen share. For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares of its common stock, par value $0.001 per share, for a total enterprise value of approximately $16 million.
Quick answer
Pyxis Oncology, Inc. is acquiring Apexigen, announced May 24, 2023. Pyxis Oncology, Inc. is based in Boston, Massachusetts, United States.
- How much did Pyxis Oncology, Inc. pay for Apexigen?
- The deal value was not disclosed.
- What does Pyxis Oncology, Inc. do?
- Pyxis Oncology is transforming the lives of patients with cancer by advancing our differentiated portfolio of biologics that specifically target tumor cells and overcome immune suppression.
- Where are Pyxis Oncology, Inc. and Apexigen based?
- Pyxis Oncology, Inc. is based in Boston, Massachusetts, United States. Apexigen is based in San Carlos, California, United States.
- Who are the decision-makers at Pyxis Oncology, Inc?
- Fundz holds 1 contact at Pyxis Oncology, Inc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Shockwave Medical Completes Acquisition Of Neovasc (April 11, 2023)
- Lilly To Acquire Dice Therapeutics To Advance Innovation In Immunology (June 20, 2023)
- Veristat Acquires European Medical Writing Consultancy Scinopsis (June 12, 2023)
- Thermo Fisher Scientific To Acquire Corevitas (July 6, 2023)
- Lilly To Acquire Sigilon Therapeutics (June 29, 2023)
- Luciole Medical Ag Announces The Acquisition Of Spiegelberg Gmbh & Co. Kg To Create A Leading Global Brain Monitoring Developer And Provider (June 27, 2023)
Who to call at Pyxis Oncology, Inc., and when
When Pyxis Oncology, Inc. changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Pyxis Oncology, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Pyxis Oncology, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Pyxis Oncology, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Pyxis Oncology, Inc. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Apexigen?
Apexigen was acquired by Pyxis Oncology, Inc., based in Boston. The deal was reported on May 24, 2023. Pyxis Oncology is transforming the lives of patients with cancer by advancing our differentiated portfolio of biologics that specifically target tumor cells and overcome immune suppression. Pyxis Oncology, Inc. is publicly traded (PYXS) and operates in Biotechnology.
When did Pyxis Oncology, Inc. acquire Apexigen?
Pyxis Oncology, Inc.'s acquisition of Apexigen was reported on May 24, 2023. Pyxis Oncology, Inc. (“Pyxis Oncology”) (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, and Apexigen, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Apexigen do?
This platform has enabled Apexigen and its collaboration partners to discover and develop therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. It is privately held, operating in Biotechnology, and is based in San Carlos.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.